Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

Majority of female kidney failure patients on dialysis may experience sexual problems

The vast majority of female kidney failure patients on dialysis may experience sexual problems, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Additional studies are needed to understand how sexual dysfunction affects dialysis patients' quality of life and psychological wellbeing.

6 Apr 2012

Only few OB-GYNs routinely inquire about patients' sexual issues

How often does your doctor ask about your sexual life? Unfortunately, the answer may be: not often enough. Leaving the subject off the check-up checklist could mean missing an important link to overall wellness.

23 Mar 2012

Virginia uproar frames abortion, contraception legislation in many states

States are grappling with reproduction-related issues after Virginia's pre-abortion ultrasound bill passed: In California, lawmakers are set to consider a bill to give more women access to early-term abortions while lawmakers in Ohio and Minnesota consider legislation on contraception.

11 Mar 2012

Contraception, abortion issues crop up in state legislatures, political races

The debate over the birth control mandate is seeping into West Virginia's governor race as reproductive-rights supporters assess their place amid losses in state legislatures.

9 Mar 2012

Neutra names new erectile dysfunction supplement as Pure Plus Powermax

Neutra Corp. announced today that its new all-natural erectile dysfunction supplement will be named Turbocharged Pure Plus Powermax.

6 Mar 2012

Abortion, contraception politics still on front burner as primaries loom

The political furor around abortion and contraception shows no sign of abating, according to news outlets.

27 Feb 2012

New erectile dysfunction supplement with Bio-Energy infusion

As Neutra Corp. works to finalize the formula for its new Pure Plus erectile dysfunction supplement, the company has already confirmed the new product's most important ingredient: The Bio-Energy infusion that will turbocharge the supplement's effectiveness.

24 Feb 2012

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.

23 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

Counterfeit anti-cancer drug Avastin raises concerns

The market is flooded with a counterfeit version of cancer drug Avastin worry doctors and patients. Injectable drugs have become increasingly attractive to counterfeiters, in part because they often fetch a higher price than regular pills.

15 Feb 2012

Debate shifts on contraception rule

While congressional Republicans say the fight isn't over on the administration's birth control mandate, the measured support for President Obama's compromise from some Catholic groups and a few Republicans has tamped down the political furor.

15 Feb 2012

NTRR completes research and development of new erectile dysfunction treatment

With Neutra Corp.'s Pure Plus weight-loss supplement already in the midst of clinical trials, the company announced today that it has completed research and development of its next product in the Pure Plus line: an all-natural erectile dysfunction (ED) treatment.

13 Feb 2012

ED can lead to potential cardiovascular disease in men

More than 12 million men have type 2 diabetes and that number is growing at an alarming rate. A little talked about complication of this disease is erectile dysfunction (ED), which can lead to an even more serious condition.

7 Feb 2012

Sex declared safe for heart patients

A doctors’ group on Thursday suggested that sex may be safe for most heart patients. The American Heart Association added that having sex only slightly raises the chance for a heart attack. And that’s true for people with and without heart disease. Despite the higher risk for a heart patient to have a second attack, there’s no evidence that they have more sex-related heart attacks than people without cardiac disease. The updated advice was released online Thursday in the heart association journal, Circulation.

22 Jan 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012.

26 Dec 2011

AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.

15 Dec 2011

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS, Inc. today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership.

9 Dec 2011